Drug intelligence / Profile preview

Wenrunxinjinpeiben

Development stage: Preclinical
Administration: Oral

Overview

Wenrunxinjinpeiben is a traditional Chinese medicine (TCM) prescription used in the management of bronchial asthma, particularly for patients classified under the "lung and kidney deficiency" syndrome according to TCM theory. The formula is administered as part of clinical studies comparing its efficacy to other TCM prescriptions for improving clinical symptoms and pulmonary function in asthma patients. The specific herbal composition, mechanism of action, and pharmacological targets are not detailed in available English-language sources. Its use is based on principles of TCM rather than modern pharmacology[1].

Brand names: Wenrunxinjinpeiben
Other names: Wenrunxinjinpeiben

Beyond the preview

Go deeper on Wenrunxinjinpeiben.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wenrunxinjinpeiben.

Explore the full profile